Is GANX or FULC more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media favor GANX or FULC?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 2 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Fulcrum Therapeutics' score of 0.26 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GANX or PYXS more profitable?

Gain Therapeutics' return on equity of -161.59% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Pyxis Oncology N/A -215.23% -112.19%

Does the media refer more to GANX or PYXS?

In the previous week, Gain Therapeutics and Gain Therapeutics both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 1.00 beat Pyxis Oncology's score of -0.40 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIK or GANX?

In the previous week, Anika Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Anika Therapeutics' score of 0.53 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GANX or STRO?

In the previous week, Sutro Biopharma had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 2 mentions for Gain Therapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat Gain Therapeutics' score of 1.00 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GANX or FATE?

In the previous week, Gain Therapeutics had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for Gain Therapeutics and 1 mentions for Fate Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Fate Therapeutics' score of 0.49 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gain Therapeutics (GANX) Competitors

$1.84 -0.11 (-5.64%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.04 (+2.17%)

As of 09/23/2026 07:30 PM Eastern

Compare

GANX vs. FULC, PYXS, ANIK, STRO, and FATE

Should you buy Gain Therapeutics stock or one of its competitors? Gain Therapeutics's main competitors and comparable companies include Fulcrum Therapeutics (FULC), Pyxis Oncology (PYXS), Anika Therapeutics (ANIK), Sutro Biopharma (STRO), and Fate Therapeutics (FATE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 2 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Fulcrum Therapeutics' score of 0.26 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 307.61%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 115.22%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Gain Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fulcrum Therapeutics' return on equity of -25.38% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than Fulcrum Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.21	N/A

Summary

Gain Therapeutics and Fulcrum Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Pyxis Oncology?

Gain Therapeutics (NASDAQ:GANX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Gain Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Gain Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A
Pyxis Oncology	$13.86M	19.38	-$79.62M	-$1.41	N/A

Gain Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 307.61%. Pyxis Oncology has a consensus price target of $8.75, indicating a potential upside of 171.74%. Given Gain Therapeutics' higher possible upside, equities analysts plainly believe Gain Therapeutics is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Gain Therapeutics' return on equity of -161.59% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Pyxis Oncology	N/A	-215.23%	-112.19%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Gain Therapeutics and Gain Therapeutics both had 2 articles in the media. Gain Therapeutics' average media sentiment score of 1.00 beat Pyxis Oncology's score of -0.40 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pyxis Oncology beats Gain Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Anika Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, Anika Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Anika Therapeutics' score of 0.53 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than Gain Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.42	-$10.88M	-$0.27	N/A
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A

Gain Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Gain Therapeutics	N/A	-161.59%	-118.36%

Anika Therapeutics presently has a consensus target price of $22.00, indicating a potential upside of 7.95%. Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 307.61%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Anika Therapeutics beats Gain Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Sutro Biopharma?

Gain Therapeutics (NASDAQ:GANX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 307.61%. Sutro Biopharma has a consensus price target of $47.30, indicating a potential upside of 200.70%. Given Gain Therapeutics' higher probable upside, research analysts plainly believe Gain Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Gain Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Sutro Biopharma	-395.25%	N/A	-88.12%

Gain Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A
Sutro Biopharma	$45.70M	5.71	-$191.09M	-$11.97	N/A

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Sutro Biopharma had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 2 mentions for Gain Therapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat Gain Therapeutics' score of 1.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gain Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Summary

Sutro Biopharma beats Gain Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Gain Therapeutics compare to Fate Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gain Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for Gain Therapeutics and 1 mentions for Fate Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Fate Therapeutics' score of 0.49 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

Gain Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 307.61%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 142.80%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Gain Therapeutics beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.11M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-3.68	13.88	274.02	25.69
Price / Sales	1,605.95	1,311.42	632.76	76.07
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.83	15.30	10.44	6.32
Net Income	-$20.16M	-$22.82M	$3.49B	$359.73M
7 Day Performance	3.37%	-1.71%	-0.66%	0.17%
1 Month Performance	-8.00%	-6.17%	-3.16%	-3.27%
1 Year Performance	5.75%	30.64%	15.15%	5.58%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.6606 of 5 stars	$1.84 -5.6%	$7.50 +307.6%	+5.1%	$85.11M	$50K	N/A	21
FULC Fulcrum Therapeutics	2.4261 of 5 stars	$3.78 -0.3%	$8.20 +116.9%	-48.2%	$289.17M	$80M	N/A	55
PYXS Pyxis Oncology	2.7656 of 5 stars	$3.33 -2.9%	$8.75 +162.8%	+47.0%	$286.09M	$13.86M	N/A	56
ANIK Anika Therapeutics	3.3795 of 5 stars	$20.91 -1.3%	$21.00 +0.4%	+123.5%	$283.58M	$112.82M	N/A	235	Analyst Forecast
STRO Sutro Biopharma	3.3869 of 5 stars	$16.56 -2.1%	$47.30 +185.6%	+89.9%	$280.39M	$102.48M	N/A	128	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. FULC, PYXS, ANIK, STRO, and FATE

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Gain Therapeutics compare to Pyxis Oncology?

Summary

How does Gain Therapeutics compare to Anika Therapeutics?

Summary

How does Gain Therapeutics compare to Sutro Biopharma?

Summary

How does Gain Therapeutics compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. FULC, PYXS, ANIK, STRO, and FATE

How does Gain Therapeutics compare to Fulcrum Therapeutics?

Does the media favor GANX or FULC?

Do analysts prefer GANX or FULC?

Is GANX or FULC more profitable?

Do institutionals & insiders hold more shares of GANX or FULC?

Which has more risk & volatility, GANX or FULC?

Which has preferable valuation & earnings, GANX or FULC?

Summary

How does Gain Therapeutics compare to Pyxis Oncology?

Which has preferable earnings & valuation, GANX or PYXS?

Do analysts recommend GANX or PYXS?

Which has more volatility & risk, GANX or PYXS?

Is GANX or PYXS more profitable?

Do insiders and institutionals have more ownership in GANX or PYXS?

Does the media refer more to GANX or PYXS?

Summary

How does Gain Therapeutics compare to Anika Therapeutics?

Which has more volatility and risk, ANIK or GANX?

Does the media favor ANIK or GANX?

Do insiders and institutionals believe in ANIK or GANX?

Which has preferable earnings & valuation, ANIK or GANX?

Is ANIK or GANX more profitable?

Do analysts prefer ANIK or GANX?

Summary

How does Gain Therapeutics compare to Sutro Biopharma?

Do analysts recommend GANX or STRO?

Is GANX or STRO more profitable?

Which has preferable valuation & earnings, GANX or STRO?

Do institutionals & insiders believe in GANX or STRO?

Does the media refer more to GANX or STRO?

Which has more volatility & risk, GANX or STRO?

Summary

How does Gain Therapeutics compare to Fate Therapeutics?

Do institutionals & insiders have more ownership in GANX or FATE?

Which has better earnings & valuation, GANX or FATE?

Does the media refer more to GANX or FATE?

Which has more risk and volatility, GANX or FATE?

Is GANX or FATE more profitable?

Do analysts rate GANX or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools